Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
Launched by MCMASTER UNIVERSITY · Dec 5, 2022
Trial Information
Current as of February 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the effectiveness and safety of different blood-thinning treatments for patients with a condition called antiphospholipid syndrome (APS) who have experienced a clotting event in their arteries within the last year. The trial is collecting information about patients receiving various treatment options, including a combination of vitamin K antagonists (VKAs) and low-dose aspirin, VKAs alone, or other blood-thinning regimens. The goal is to determine which treatment works best at preventing further blood clots while keeping patients safe.
To be eligible for this trial, participants must be at least 18 years old, have a confirmed diagnosis of antiphospholipid syndrome, and have had a recent arterial clotting event. They should also be receiving one of the specified blood-thinning treatments. If you join the study, you can expect to be followed for two years, during which researchers will monitor your health and the effects of your treatment. This trial is currently recruiting participants, and it’s important to discuss with your doctor if this study might be right for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients of at least 18 years of age with confirmed antiphospholipid syndrome according to Sydney criteria and with first or recurrent arterial thrombotic manifestation, including those with asymptomatic brain infarcts on diagnostic imaging.
- • 2. Treatment with either A) a vitamin K antagonist (VKA) with therapeutic range, international normalized ratio (INR) 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0 or C) VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen, if considered appropriate by the treating physician.
- • 3. Signed informed consent obtained (in jurisdictions where required).
- Exclusion Criteria:
- • 1. Inability to follow the patient due to geographical or other reasons.
- • 2. Patients with documented poor compliance.
- • 3. Bleeding risk that in the opinion of the treating physician makes combination antithrombotic therapy unsafe.
- • 4. Pregnancy or planned pregnancy.
- • 5. Venous thrombotic event diagnosed after the last arterial event.
Trial Officials
Cary Clark
Study Director
International Society on Thrombosis and Haemostasis
About Mcmaster University
McMaster University, a leading research institution located in Hamilton, Ontario, Canada, is renowned for its innovative approach to education and its commitment to advancing healthcare through rigorous clinical research. The university's diverse research programs are supported by a multidisciplinary team of experts dedicated to improving patient outcomes and public health. With a strong emphasis on evidence-based medicine, McMaster University actively engages in clinical trials that explore new therapies, interventions, and health technologies, fostering collaboration among researchers, healthcare professionals, and industry partners to translate findings into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Córdoba, , Argentina
Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
Hamilton, Ontario, Canada
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials